



RealM Therapeutics

Non-confidential Corporate Presentation

September 2018

NASDAQ/AIM:RLM

Important Information

This presentation contains information pertaining to Realm Therapeutics plc ("Realm"), and has been prepared by Realm solely for your information in connection with its use at a presentation for the purpose of providing background information on Realm, its business and the industry in which it operates. For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meeting. This presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of Realm or its subsidiaries, or their respective directors, officers, employees, agents, affiliates and advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in the presentation is subject to verification, correction, completion and change without notice. In giving this presentation, none of Realm or any of its subsidiaries or any of their respective directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any additional information that may arise in connection with it. This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of Realm in any jurisdiction or an inducement to enter into investment activity, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation does not purport to contain all of the information that may be required to evaluate any investment in Realm or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in Realm should be independently evaluated and any person considering such an investment in Realm is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making such an investment.

Matters discussed in this presentation may constitute forward-looking statements, including those relating to Realm's projected financial results and trends, business plans and prospects, and the development of product candidates in Realm's clinical development pipeline, including clinical trial results and the status of regulatory review thereof. The forward-looking statements contained in this presentation reflect Realm's views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause Realm's actual results, performance or achievements to differ significantly from those expressed or implied in any forward-looking statement. Some of the key factors that could cause actual results to differ from Realm's expectations include: changes in Realm's business strategy, including due to the ongoing strategic review of its business and its ability to identify, acquire and in-license additional product candidates; developments in respect of its HOCI technology and the clinical development of its product candidates, including the receipt and analysis of data from clinical trials and preclinical studies for its product candidates, related regulatory matters, and the commercialization and market acceptance thereof; and changes in Realm's manufacturing capabilities and intellectual property position. For further information regarding these risks, uncertainties and other factors that could cause Realm's actual results to differ from Realm's expectations, you should read Realm's Annual Report for the year ended December 31, 2017 posted on www.realmtx.com and the Risk Factors contained in Exhibit 99.3 to its Current Report on Form 6-K furnished to the SEC on September 17, 2018. No reliance should be made on such forward-looking statements. While Realm may elect to update the information in this presentation, including any such forward looking statements, in the future, Realm undertakes no obligation to do so on account of new information, future events or otherwise, except as required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

To the extent applicable, the data contained in this presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed by Realm to be reliable, but that there is no guarantee of the accuracy or completeness of such data. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size, growth, and other data about Realm's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of Realm's future performance and the future performance of the markets in which Realm operates are necessarily subject to a high degree of uncertainty and risk. While Realm believes that each of these publications, studies and surveys has been prepared by a reputable source, Realm has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from the Realm's own internal research and estimates based on the knowledge and experience of Realm's management in the market in which Realm operates. While Realm believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation.

Corporate Assets

- Public Stock Listings – Nasdaq and AIM
- Cash at August 31, 2018 of \$21.3M
 - Recent actions taken (including reduction in headcount & suspension of all clinical development and R&D programs) to minimize cash burn
- ~\$1.1M annual royalty stream from out-licensed medical device - Vashe[®] wound care products
- 510(k)-cleared anti-itch hydrogel (previously marketed as Aurstat[™])
- Patent portfolio related to proprietary hypochlorous acid (HOCl) technology, including product candidates with FDA IND clearance
- Experienced management team
- Office/lab space (~7500 sq feet) in Malvern, PA with lease through March 2025

Public Listings

- Public Listings – Nasdaq and AIM (ticker: RLM)
- 116,561,917 ordinary shares outstanding
 - ~36% of shares are outstanding as ADSs (25:1 ratio)
 - Fully diluted shares
 - ~27M warrants outstanding (most exercisable at 58 pence)
 - ~11M employee/director options outstanding (all underwater)
- Top 9 shareholders own ~79% of outstanding shares
 - OrbiMed, BVF Partners, RA Capital, Invesco, Abingworth
- Market cap = \$14.6M as of September 17, 2018
- D&O Insurance (for dual listings) paid through June 2019

US GAAP Balance Sheet at June 30, 2018 (in 000's)

Assets	
Current assets:	
Cash and cash equivalents	\$ 16,236
Marketable securities	7,433
Royalty receivable	757
Prepaid expenses and other assets	203
Total current assets	24,629
Property and equipment, net	252
Royalty receivable, net of current portion	1,570
Other assets	280
Total assets	\$ 26,731
Liabilities and Shareholders' Equity	
Current liabilities:	
Accounts payable	\$ 1,233
Accrued expenses	1,216
Total liabilities	2,449
Shareholders' equity:	24,282
Total liabilities and shareholders' equity	\$ 26,731

Vashe Wound care Royalty

- **Annual Royalty Cashflow:** ~\$1.1M (growing)
- **Product:** Prescription 510(k)-cleared device Vashe[®] wound care (based on Realm's proprietary HOCl technology)
- **Partner:** SteadMed Medical
- **Indications for Use:** Intended for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms and debris from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites; and exit sites. It is also intended for moistening and lubricating absorbent wound dressings.
- **Out-licensed:** April 2013
- **Currently Marketing Focus:** United States



Aurstat™ Anti-Itch Hydrogel Product Overview



Indications for Use: Aurstat™ Anti-Itch Hydrogel is indicated for the management and relief of pain, burning and itching experienced with various dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis, as well as for the relief of pain from first and second degree burns, and aids to relieve dry waxy skin by maintaining a moist wound and skin environment. A moist wound and skin environment is beneficial to the healing process.

Aurstat™ (0.045% HOCl) Medical Device Opportunity




- Cleared by FDA as a medical device for management and relief of pain, burning, and itching associated with various dermatoses
- Based on Realm's proprietary HOCl technology
- Out-licensed and launched in 2013 under royalty arrangement; ~20,000 prescriptions in 18 months post-launch (2014 Sales: ~\$2.5M)
- Terminated out-licensing agreement at the end of 2014 and suspended sales in order to develop topical HOCl formulation as a drug
- Possibility to out-license this medical device

Aurstat Investigator Study

- Dr. Brian Berman conducted a blinded, randomized trial using Aurstat™ in 30 subjects with mild to moderate AD
- Evaluated the effects vs untreated control
- Assessed pruritis and tolerability at baseline through Day 3:
 - VAS Scale used to measure pruritis
 - Investigator and subject assessment of tolerability (see next slide for results)

Itch Reduction in 74% of Subjects With Aurstat™



p=0.007

Berman, B., Cash, K., Frisina, A., Swenson, N., Kollman, E., Nestor, M. (2013). Evaluation of an Anti-Itch Hydrogel Containing 0.045% HOCl versus Untreated Control in the Treatment of Atopic Dermatitis Associated Pruritus. *Fall Clinical Dermatology Conference*, Las Vegas, NV.



Aurstat™ Case Study



Clinical Case Baseline

10-year-old female with pruritus associated with Atopic Dermatitis. Patient's parent requested a product that was not a steroid. Physician prescribed Aurstat Anti-Itch Hydrogel BID.



Week 8

Patient returned after 8 weeks with much improvement. Reported discontinuing use of the product after 4 weeks as symptoms had resolved.

Case study reflects one patient's experience

Prior Positioning/Marketing

Relieve the itch with Aurstat® Anti-Itch



**ITCH CONTROL MEANS
DAMAGE
CONTROL
IN ATOPIC DERMATITIS**

The itch of atopic dermatitis leads to scratching, and scratching means damage.
**At the first urge to itch—
reach for Aurstat® Anti-Itch.**



Indication
Aurstat® Anti-Itch Hydrogel is indicated for the management and relief of pain, burning, and itching experienced with various dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis, as well as for the relief of pain from first and second degree burns, and aids to relieve dry waxy skin by maintaining a moist wound and skin environment. A moist wound and skin environment is beneficial to the healing process.

Aurstat® Anti-Itch Hydrogel— Engineered for use at the very first urge to itch!

Patented, pH-optimized formulation in a cosmetically elegant hydrogel

- Contains 0.045% hypochlorous acid (HOCl) as a preservative
 - HOCl is a key component of bleach baths
- Safe and well tolerated^{1,3}
 - Alcohol free, fragrance free
 - Non-irritating, non-sensitizing, and non-cytotoxic
 - Safe to use on the face
 - Avoid contact with the eyes
 - No age restrictions

Issued Patents Create Strong IP Portfolio for HOCl

- Composition of Matter
 - 8,871,278: Stabilized hypochlorous acid solutions – 2032
 - 9,414,584: Stabilized hypochlorous acid solutions – 2032
- Method of Use
 - 9,381,214: Method of treating irritation of the skin – 2032
 - 8,877,257: Method and compositions for treating conditions associated with infection and/or inflammation – 2031
- Method of Manufacture
 - 7,897,023: Device for producing anodic oxidation products of an alkali or alkali-earth metal chloride solution - 2028

IP Portfolio Offers Potential Extended Applications

- 15 US and 21 International Patents Issued; 8 US and 29 International Patents Pending; 2 in-licensed Patents
- Dermatology & Ophthalmology product candidates, underpinned by IP, which have FDA cleared INDs
- IP covers healthcare, industrial, veterinary/husbandry, food safety, agricultural and consumer applications for Realm's proprietary HOCl technology, including
 - Wound/Burn/Ulcer treatment
 - Treatment of Infected Tissues (including *C. difficile*)
 - Hard Surface Disinfection
 - Hospital Infection Control and Prevention (including body wash, hand sanitizer, health care antiseptic hand washes/rubs and equipment disinfection)
 - Water Treatment/Disinfection (including fracking)
 - Treating and/or preserving food products
 - Treating and/or preserving cut flowers

Certain applications above are out-licensed under existing agreements and others represent potential opportunities

Experienced Management Team

Alex Martin
CEO



Marella Thorell
CFO /COO



Christian Peters, M.D., Ph.D.
CMO



Cary Schockemoehl
VP, Business Development

